According to CoinMeta, on November 6th, Novartis showcased its innovative drug under development in the field of immunology, Ianalumab, for the first time at the 9th China International Import Expo (CIIE), presenting its research progress in the area of Sjögren's syndrome through this "first exhibition in China." Gao Rong, the head of Novartis' pharmaceutical development department in China, stated that the CIIE provides an excellent platform for the company to display its global innovation achievements, and China is becoming one of the global launch markets for Novartis' breakthrough therapies.